Gallbladder Cancer Treatment Market to Gain from the Growing Sedentary Lifestyle Reported Worldwide-MAZZ Home
Global Gallbladder Cancer Treatment Market to Witness Impressive Growth Backed by the Rising Tobacco Consumption, says Fortune Business Insights
The Global Gallbladder Cancer Treatment Market is expected to gain impetus from a rise in the sedentary lifestyle amongst the populace. According to Fortune Business Insights, in an upcoming report, titled, “Gallbladder Cancer Treatment Market Size, Share and Global Trend By Indication (Stage I, Stage II, Stage II, Stage IV), By Treatment (Radiation Therapy, Chemotherapy, Immunotherapy, Others), By End User (Hospitals, Gynecology Clinics, Academic and Research Centers, Others) and Geography Forecast till 2026,” rapid growth of smoking and tobacco consumption are projected to drive the global gallbladder cancer treatment market growth during the forecast period. Moreover, the report states that key market players across the world are introducing new drugs for the treatment of gallbladder cancer. This is another significant factor that will propel the gallbladder cancer treatment market in the coming years.
Introduction of Technologically Advanced Drugs to Propel the Chemotherapy Segment
The report further classifies the global gallbladder cancer treatment market on the basis of type, treatment, end-use, and geography. In terms of treatment, the market is grouped into immunotherapy, chemotherapy, radiation therapy, and others. Out of these, the chemotherapy segment was leading the global gallbladder cancer treatment market in terms of revenue in the year 2018. The growth is attributed to the introduction of latest drugs for the treatment of chemotherapy in the market. Fortune Business Insights predicts that this segment will retain its position throughout the forecast period.
- Stage I
- Stage II
- Stage II
- Stage IV
- Radition Therapy
- Gynecology Clinics
- Academic and Research Centres
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East and Africa (South Africa, GCC and Rest of Middle East and Africa)
Key players leading the global surgical robots market include
- Boston Scientific Corporation,
- Intuitive Surgical,
- R. Bard, Inc.,
- Dornier MedTech,
- Koninklijke Philips N.V.,
- Braun Melsungen AG,
Increasing Demand for Treatment Options to Favor Growth in North America
The global gallbladder cancer treatment market is geographically divided into the Middle East and Africa, Europe, North America, Latin America, and Asia Pacific. Amongst these regions, in 2018, North America was in a dominant position in the global gallbladder cancer treatment market. The region will remain in its position in the forthcoming years due to the increasing incidence of gallbladder cancer that is likely to create huge demand for multiple treatment options. Additionally, higher per capita expenditure on healthcare and expensive nature of therapies are projected to fuel the gallbladder cancer treatment market revenue in North America. The American Cancer Society also declared that approximately 11,740 cases of gallbladder cancer were diagnosed in North America in the year 2017.
Key Market Players Focus on Innovative Product Launches to Gain Fast Track Approvals
EMD Serono, Inc., a prominent leader in the biopharmaceutical industry, based in the U.S., announced in May 2017 that it has received FDA approval for the Bavencio (avelumab), the company’s immunotherapy drug. The drug can be used to treat patients suffering from metastatic Merkel cell carcinoma (MCC) and those who are 12 years and older. FDA approved the product based on data from a single-arm, open label, multi-center trial that aided in demonstrating a clinically durable and meaningful overall response rate.
- Hoffmann-La Roche Ltd., a multinational healthcare company, headquartered in Switzerland, announced in May 2016 that it has bagged FDA approval for TECENTRIQ (atezolizumab), its new immunotherapy drug. According to the company, the drug is the first cancer immunotherapy that has been approved by FDA. The drug will be mainly used for the treatment of metastatic non-small cell lung cancer (NSCLC). It targets the PD-L1 protein, which plays a very important role in the functioning of the medicine. Overall, numerous enterprises have begun focusing on launching technologically advanced drugs to gain FDA approvals for marketing purposes.
Fortune Business Insights has profiled few of the key market players operating in the global gallbladder cancer treatment market. They are Sanofi, Boston Scientific Corporation, Intuitive Surgical, B. Braun Melsungen AG, Dornier MedTech, Koninklijke Philips N.V., C. R. Bard, Inc., and other prominent market players.
More Trending Topics From Fortune Business [email protected]
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit Gallbladder Cancer Treatment Market to Gain from the Growing Sedentary Lifestyle Reported Worldwide